New Frontiers for Neurology Laboratory Medicine



Ultrasensitive immunoassays have launched an explosion of research on blood biomarkers for a variety of neurological indications, spanning acute conditions such as traumatic brain and spinal cord injury to chronic conditions including multiple sclerosis, neurodegenerative disease, and dementia.

This webcast will focus on neurology blood biomarker research, highlighting Canadian assets that can be leveraged toward analytical and clinical validation studies.

Key Learning Points:

  • How ultra-sensitivity allows for greater depth of exploration in neurological research
  • Which immunoassays are currently most prevalent in neurological research
  • The analytical and clinical validation process and how to use ultrasensitive immunoassays to achieve it

About the Speaker:

Dr. Cheryl Wellington, Professor 

Department of Pathology and Laboratory Medicine 

University of British Columbia

Dr. Cheryl Wellington is a professor at the University of British Columbia whose research is highly multidisciplinary with major efforts in Alzheimer’s Disease and Traumatic Brain Injury. Her laboratory is the leading Canadian site for research on blood biomarkers using the Quanterix single molecule array (Simoa) platform. 

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.